Invention Number:
12_2712
Brain injury is a major medical and socio-economic problem globally and is one of the leading causes of death and disability. 'Genistein' is a neuroprotective treatment for brain injury.
Background
Traumatic brain injury is a major medical and socio-economic problem globally and is one of the leading causes of death and disability.
A stroke is a medical emergency and can cause permanent neurological damage and death. Risk factors for stroke include old age, high blood pressure, previous stroke or transient ischemic attack (TIA), diabetes, high cholesterol, tobacco smoking and atrial fibrillation.
Stroke is the second leading cause of death worldwide.
The Technology
This invention has arisen from our discovery of a novel isoform of the TRPC3 ion channel subunit (TRPC3c) which has notably stronger activation and associated Ca2+ entry than previously identified isoforms. We have shown that expression of this TRPC3c isoform is regulated in the brain, and that the channel activity of TRPC3c channels is potently blocked by genistein and PyR3, another TRPC channel blocker.
Key Benefits
- Currently no known treatments for stroke
- TRPC3(c) drug target for ischaemic/excitotoxic brain injury
- Treatment of epileptic seizures
- Traumatic brain injury neuroprotection
The Opportunity
UNSW is seeking a commercial partner to licence and/or to work collaboratively with the inventor Professor Gary Housley in the development of this potentially disruptive therapeutic agent.
